Also found in: Dictionary, Wikipedia.
Pharmacologic class: Folic acid antagonist
Therapeutic class: Antiprotozoal, antimalarial
Pregnancy risk category C
Inhibits reduction of dihydrofolic acid to tetrahydrofolic acid (folinic acid) by binding to and reversibly inhibiting dihydrofolate reductase
Tablets: 25 mg
Indications and dosages
➣ To control plasmodia transmission and suppress susceptible strains Adults and children ages 10 and older: 25 mg P.O. daily for 2 days, given with a sulfonamide
Adults: Initially, 50 to 75 mg P.O. daily for 1 to 3 weeks, given with a sulfonamide. Depending on response and tolerance, reduce dosages of both drugs by 50% and continue therapy for 4 to 5 more weeks.
Children: 1 mg/kg P.O. daily in two equally divided doses for 2 to 4 days, then reduced to 0.5 mg/kg/day for approximately 1 month. Alternatively, 2 mg/kg (up to 100 mg) P.O. daily in two equally divided doses for 3 days, then 1 mg/kg (up to 25 mg) in two equally divided doses for 4 weeks, given with sulfadiazine for 4 weeks.
➣ Prophylaxis of malaria caused by susceptible plasmodia strains
Adults and children older than age 10: 25 mg P.O. weekly
Children ages 4 to 10: 12.5 mg P.O. weekly
Infants and children younger than age 4: 6.25 mg P.O. weekly
• Prophylaxis of Pneumocystis jiroveci pneumonia
• Hypersensitivity to drug
• Megaloblastic anemia caused by folate deficiency
• Concurrent folate antagonist therapy
Use cautiously in:
• anemia, bone marrow depression, hepatic or renal impairment, G6PD deficiency
• history of seizures
• patients more than 16 weeks pregnant
• breastfeeding patients.
• Administer with meals.
• When giving tablets to young children, crush them and administer as oral suspension in water, cherry syrup, or sweetened solution.
• Know that because of worldwide resistance to pyrimethamine, its use alone to prevent or treat acute malaria is no longer recommended.
• Be aware that fixed combination of pyrimethamine and sulfadoxine is available and has been used for uncomplicated mild to moderate malaria caused by chloroquineresistant Plasmodium falciparum and for presumptive self-treatment by travelers.
CNS: headache, light-headedness, insomnia, malaise, depression, seizures
EENT: dry throat
GI: nausea, vomiting, diarrhea, anorexia, atrophic glossitis
Hematologic: megaloblastic anemia, leukopenia, pancytopenia, thrombocytopenia
Respiratory: pulmonary eosinophilia
Skin: pigmentation changes, dermatitis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome
Other: fever, anaphylaxis
Drug-drug. Lorazepam: hepatotoxicity Myelosuppressants (including antineoplastics): increased risk of bone marrow depression
Drug-diagnostic tests. Platelets, white blood cells: decreased counts
• Monitor CBC. Watch for evidence of blood dyscrasias.
• Assess for signs and symptoms of folic acid deficiency.
• Closely monitor neurologic and cardiovascular status. Stay alert for seizures and arrhythmias.
☞ Watch for evidence of erythema multiforme, including sore throat, cough, mouth sores, rash, iritic lesions, and fever. Report early signs before condition can progress to Stevens-Johnson syndrome.
• Advise patient to take with meals.
☞ Tell patient to discontinue drug and contact prescriber at first sign of rash.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.